Gross proceeds of approximately $2.4 million from sale of PAVmed securities priced at-the-market and Veris common stock priced at a $35 million pre-money valuation NEW YORK , Feb. 24, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiary, Veris Health Inc, ("Veris") today announced that the companies have completed a $2.37 million private placement financing as detailed in Form 8-K filed with the SEC on February 21, 2025. Accredited investors purchased PAVmed securities priced at-the-market and shares of Veris common stock reflecting a pre-money Veris valuation of approximately $35 million.
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that on February 14, 2025, PAVmed received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the Nasdaq Capital Market's Continued Listing Standards for Primary Equity Securities, and its securities will continue to be listed and traded on The Nasdaq Capital Market. The Company regained compliance under Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain stockholders' equity of at least $2,500,000.
Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK , Sept.
PAVmed Inc. (NASDAQ:PAVM ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Matt Riley - Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference Call Participants Matthew Park - Cantor Fitzgerald Anthony Vendetti - Maxim Group Ed Woo - Ascendiant Capitalized Operator Good morning and welcome to PAVmed's Second Quarter 2024 Business Update Conference Call. At this time, all lines are in a listen-only mode.
A conference call and webcast will be held at 8:30 AM Eastern Time on May 14, 2024 by PAVmed Inc. to provide a business update.
PAVmed Inc. (PAVM) ended the most recent trading session at $2.07, showing a decrease of 1.43% from the previous day.
PAVmed Inc. (NASDAQ:PAVM ) Q3 2023 Earnings Call Transcript November 15, 2023 8:30 AM ET Company Participants Michael Parks - Vice President of Investor Relations Lishan Aklog - Chairman and Chief Executive Officer Dennis McGrath - Executive Vice President and Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Ed Woo - Ascendiant Capital Anthony Vendetti - Maxim Group Operator Good day, and welcome to the PAVmed Third Quarter 2023 Business Update Conference Call. All participants will be in a listen-only mode.
PAVmed Inc. (PAVM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
PAVmed Inc. (NASDAQ:PAVM ) Q2 2023 Earnings Conference Call August 16, 2023 8:30 AM ET Company Participants Michael Parks - Vice President of Investor Relations Lishan Aklog - Chairman and Chief Executive Officer Dennis McGrath - Executive Vice President and Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Ed Woo - Ascendiant Capital Ross Osborn - Cantor Fitzgerald Anthony Vendetti - Maxim Group Operator Good day, and welcome to the PAVmed Second Quarter 2023 Business Update Conference Call. [Operator Instructions] Please note, today's event is being recorded.